Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: Beltropolis Boy who wrote (616)	5/15/1998 10:16:00 PM
From: Ricardo A. Biondi	Read Replies (1) \| Respond to of 900

FOR IMMEDIATE RELEASE- more - Contact: The Liposome Company, Inc. Lawrence Hoffman, CFO (609) 452-7060 Noonan Russo Communications (212) 696-4455 Ernie Knewitz (media) ext. 204 Barbara Lindheim (investor) ext. 237 THE LIPOSOME COMPANY PRESENTS DATA ON PROMISING NEW ANTICANCER DRUGS Princeton, NJ -- May 15, 1998 -- In response to a question at its annual meeting of shareholders in Princeton, NJ Thursday, The Liposome Company highlighted data on some of its early stage compounds. This data had previously been presented at scientific meetings, published in scientific journals or disclosed in issued U.S. patents. A shareholder asked how the Company had reacted to recently publicized antiangiogenic compounds. Dr. Andrew Janoff , Vice President of Research and Development, said that the Company is dedicated to developing a family of bioactive lipids that are expected to be less compromising to patients than are standard chemotherapeutics available today. He then presented data showing that two of the Companys drugs in pre-clinical trials have been tested successfully in tumor-bearing mice. One of these drugs, a liposomal ether lipid known as TLC ELL-12, kills cancer cells by apoptosis. Its active ingredient has been shown to destroy one million cancer cells for every normal cell, which likely will make it a highly selective antitumor agent. An article that was recently published in the scientific journal, Cancer Research, reported that TLC ELL-12 was effective against various types of tumors in mice. It concluded that in addition to directly killing tumor cells and stimulating the hosts own anticancer defenses, this compound could also act as an antiangiogenic agent, suppressing the growth of new blood vessels to feed the tumor cells. Dr. Janoff also showed data from studies of the Companys proprietary bromotaxol, a prodrug of the widely-used chemotherapeutic, TAXOLr. In a mouse model of human ovarian cancer, all animals treated with bromotaxol survived and appeared to be healthy at the end of the year-long trial; whereas all those treated with TAXOLr died from the disease. Dr. Janoff noted that although anticancer products, including those in The Liposome Companys preclinical pipeline, may perform well in animal models, a degree of caution is warranted. The true potential of a product will not be evident until after the product has performed in controlled human studies. The Liposome Company is a biopharmaceutical company developing and marketing therapeutic products to treat cancer and related diseases. ABELCETr (Amphotericin B Lipid Complex Injection) which has been approved in 20 countries, is marketed in the United States for the treatment of severe, systemic fungal infections in patients who are refractory to or intolerant of conventional therapy and is the leading lipid-based formulation of amphotericin B in this country. Preparations are underway to file a New Drug Application in the U.S. for the Companys second drug, EVACET* (formerly TLCD-99) liposomal doxorubicin, to treat metastatic breast cancer. The Companys product pipeline includes TLCELL-12 and bromotaxol for the treatment of various cancers and programs focused on the development of new cancer therapies and vehicles for the delivery of gene therapy. *********************************************************************************** Except for historical information, this press release contains forward-looking statements that involve risks and uncertainties, including but not limited to statements regarding the successful filing and/or marketing of EVACET, TLCELL-12, Bromotaxol or any other product in development. While these statements reflect the Companys best current judgment, they are subject to risks and uncertainties that could cause actual results to vary, including the risk factors identified in the Registration Statement on Form S-3 dated October 29, 1997 and from time to time in the Companys other SEC filings. ˜˜˜˜˜˜˜˜˜˜˜˜˜˜˜˜˜˜˜ Please visit our web site at: lipo.com If you no longer wish to receive these mailings, you can unsubscribe just by sending e-mail to: LISTSERV@LISTSERV.LIPO.COM with SIGNOFF LIPOSOME-PRESS on a line all by itself in the body of the message. Technical problems with the mailing list or our web site should be sent to: Webmaster@lipo.com